


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A tetrahydroquinoline represented by the following formula (I), or pharmacologically acceptable salts thereof:



where R¹ represents ~~a nitro group~~ or a cyano group;

i represents 0;

X represents an alkylene group having 1 - 5 carbon atoms which may be substituted by a substituent selected from the group consisting of an alkyl group having 1 - 6 carbon atoms and a cycloalkyl group having 3 - 7 carbon atoms;

Y represents ~~-NR³CO-~~, ~~-NR³SO₂-~~, ~~-NR³CONH-~~ or ~~-NR³CSNH-~~,

wherein R³ represents a hydrogen atom, an alkyl group having 1 - 6 carbon atoms, a cycloalkyl group having 3 - 7 carbon atoms, or an aralkyl group having 7 - 9 carbon atoms; and

R² is a phenyl group having substituent R⁴ at 4-position, or a ~~6-membered heteroaryl~~ pyridyl group having substituent R⁴' at 4-position, wherein R⁴ and R⁴' independently represent a

halogen atom, $-O-R^{5A}$, or $-NHCO-R^{5A}$, wherein R^{5A} represents a hydrogen atom, or an alkyl group having 1-6 carbon atoms which may be substituted by a fluorine atom.

2. (currently amended): The tetrahydroquinoline or pharmacologically acceptable salts thereof according to claim 1,

wherein X is $-C(CH_3)_2-CH_2-$ and Y is $-NHCO-$ or $-NHCONH-$.

3. - 5. (canceled).

6. (currently amended): The tetrahydroquinoline or pharmacologically acceptable salts thereof according to claim 51,

wherein R^4 and $R^{4'}$ independently represent $-NHCO-R^{5A}$.

7.-8. (canceled).

9. (withdrawn- currently amended): A pharmaceutical comprising the tetrahydroquinoline or pharmacologically acceptable salts thereof according to any one of claims 1, 2, ~~3, 5~~ and 6 as an active ingredient.

10. (withdrawn): The pharmaceutical according to claim 9 which is an androgen receptor agonist.

11. (withdrawn): The pharmaceutical according to claim 10 which can be used in preventing or treating osteoporosis or wasting disease.

12. (withdrawn): The pharmaceutical according to claim 10 which can be used in preventing or treating a disease selected from the group consisting of male hypogonadism, male sexual dysfunction, abnormal sex differentiation, male delayed puberty, carcinoma of female genitalia, breast cancer, mastopathy, endometriosis and female sexual dysfunction.

13. (withdrawn): The pharmaceutical according to claim 10 which can be used in preventing or treating hematopoietic dysfunction and a disease related thereto.

14. (withdrawn- currently amended): A method for preventing or treating wasting disease or osteoporosis, comprising administering the tetrahydroquinoline or pharmacologically acceptable salts thereof according to any one of claims 1, 2, ~~3, 5~~ and 6, in an amount effective for prevention or treatment of such disease, to a mammal requiring such prevention or treatment.

15. (withdrawn- currently amended): A method for preventing or treating a disease selected from the group consisting of male hypogonadism, male sexual dysfunction, abnormal sex differentiation, male delayed puberty, carcinoma of female genitalia, breast cancer, mastopathy, endometriosis and female sexual dysfunction, said method comprising administering the tetrahydroquinoline or pharmacologically acceptable salts thereof according to any one of claims 1, 2, ~~3, 5~~ and 6, in an amount effective for prevention or treatment of such disease, to a mammal requiring such prevention or treatment.

AMENDMENT UNDER 37 C.F.R. § 1.116
Application No.: 10/522,553

16. (withdrawn- currently amended): A method for preventing or treating hematopoietic dysfunction and a disease related thereto, said method comprising administering the tetrahydroquinoline or pharmacologically acceptable salts thereof according to any one of claims 1, 2, ~~3, 5~~ and 6, in an amount effective for prevention or treatment of such disease, to a mammal requiring such prevention or treatment.